Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures: 2010-2025
Historic Gains from Sales and Divestitures for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Sep 2025 value amounting to $67,000.
- Lineage Cell Therapeutics' Gains from Sales and Divestitures changed negligibly% to $67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $67,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $67,000 for FY2024, which is 16.25% down from last year.
- As of Q3 2025, Lineage Cell Therapeutics' Gains from Sales and Divestitures stood at $67,000, which was down 0.00% from $67,000 recorded in Q2 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Gains from Sales and Divestitures peaked at $80,000 during Q1 2023, and registered a low of $16,000 during Q1 2021.
- Its 3-year average for Gains from Sales and Divestitures is $71,727, with a median of $67,000 in 2025.
- As far as peak fluctuations go, Lineage Cell Therapeutics' Gains from Sales and Divestitures crashed by 50.00% in 2022, and later surged by 400.00% in 2023.
- Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Gains from Sales and Divestitures stood at $62,000 in 2021, then tumbled by 50.00% to $31,000 in 2022, then soared by 158.06% to $80,000 in 2023, then fell by 16.25% to $67,000 in 2024, then remained steady at $67,000 in 2025.
- Its last three reported values are $67,000 in Q3 2025, $67,000 for Q2 2025, and $67,000 during Q1 2025.